Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Celldex (CLDX – Research Report). The associated price target was lowered to $50.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Celldex’s promising data on barzolvolimab (barzo) for chronic spontaneous urticaria (CSU). At the European Academy of Allergy and Clinical Immunology ’25, Celldex presented 76-week data from its Phase 2 trial, showing significant improvements in disease control and quality of life for patients. The data highlighted that a substantial portion of patients achieved complete response or maintained well-controlled disease, with minimal impact on their quality of life.
Moreover, barzo demonstrated a strong safety profile, with side effects being rare, mild, and reversible. This positions barzo as a potentially best-in-class treatment option for CSU, offering effective and safe long-term outcomes across diverse patient groups. The therapy’s ability to provide durable responses in a challenging indication enhances its market potential, distinguishing it in a competitive landscape. These compelling results and the ongoing Phase 3 trials contribute to the positive outlook for Celldex’s stock.
Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Actinium Pharmaceuticals, and Kura Oncology. According to TipRanks, Pantginis has an average return of -17.3% and a 28.83% success rate on recommended stocks.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $43.00 price target.